The HAEi Global Access Program (GAP) is a landmark medication access program. It aims to make modern HAE-specific therapy available to patients who live where these medicines are not yet commercially available. It is thought that this is the first medication distribution program of its type to be initiated by a patient organization.
The GAP program works through a Named Patient Program. This allows governments and hospitals to order medicine for individual patients.
At present, the program enables Ruconest, an HAE-specific therapy produced by Pharming Group, to be supplied to all countries where it is not commercially available.
HAEi GAP is run in partnership with the medicines access company Inceptua.
For more information, please contact info@haei.org
HAEi Global Access Program
Click below to download the HAEi GAP flyers:
“The HAEi Global Access Program brings the opportunity of access to HAE medications in countries where modern therapies are otherwise unavailable. This is the first program of its kind in HAE, and we believe the first time this type of program has been initiated by a patient organization.”
“HAEi is committed to securing access to HAE medications for patients across the globe. We are extremely proud to have established HAEi GAP with our current partners and will continue to work with other manufacturers with the hope of expanding the program in the future.”
